Published in Infect Immun on October 01, 1992
Intracellular growth in Acanthamoeba castellanii affects monocyte entry mechanisms and enhances virulence of Legionella pneumophila. Infect Immun (1999) 1.93
Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci U S A (1998) 1.74
Legionella pneumophila entry gene rtxA is involved in virulence. Infect Immun (2001) 1.52
Activation of human monocytes by live Borrelia burgdorferi generates TLR2-dependent and -independent responses which include induction of IFN-beta. PLoS Pathog (2009) 1.47
Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of Borrelia burgdorferi and cytokine induction. Infect Immun (2008) 1.40
Entry of Borrelia burgdorferi into macrophages is end-on and leads to degradation in lysosomes. Infect Immun (1996) 1.17
Nitric oxide production during murine Lyme disease: lack of involvement in host resistance or pathology. Infect Immun (1995) 1.11
Coiling phagocytosis of trypanosomatids and fungal cells. Infect Immun (1998) 1.02
Identification of a gene that affects the efficiency of host cell infection by Legionella pneumophila in a temperature-dependent fashion. Infect Immun (2003) 0.99
Elastase is the only human neutrophil granule protein that alone is responsible for in vitro killing of Borrelia burgdorferi. Infect Immun (1998) 0.98
Use of CFSE staining of borreliae in studies on the interaction between borreliae and human neutrophils. BMC Microbiol (2006) 0.96
Dendritic cells phagocytose and are activated by Treponema pallidum. Infect Immun (2001) 0.94
Downstream signals for MyD88-mediated phagocytosis of Borrelia burgdorferi can be initiated by TRIF and are dependent on PI3K. J Immunol (2009) 0.94
Coiling phagocytosis discriminates between different spirochetes and is enhanced by phorbol myristate acetate and granulocyte-macrophage colony-stimulating factor. Infect Immun (1998) 0.90
Coiling phagocytosis of Borrelia burgdorferi by primary human macrophages is controlled by CDC42Hs and Rac1 and involves recruitment of Wiskott-Aldrich syndrome protein and Arp2/3 complex. Infect Immun (2001) 0.90
Tube phagocytosis, a novel way for neutrophils to Phagocytize borrelia burgdorferi. Infect Immun (1998) 0.89
The formins FMNL1 and mDia1 regulate coiling phagocytosis of Borrelia burgdorferi by primary human macrophages. Infect Immun (2013) 0.89
Borrelia burgdorferi induces chemokines in human monocytes. Infect Immun (1997) 0.87
Mechanisms of Borrelia burgdorferi internalization and intracellular innate immune signaling. Front Cell Infect Microbiol (2014) 0.86
The effects of macrophage source on the mechanism of phagocytosis and intracellular survival of Leishmania. Microbes Infect (2011) 0.85
Phagosomal TLR signaling upon Borrelia burgdorferi infection. Front Cell Infect Microbiol (2014) 0.85
Macrophages and enriched populations of T lymphocytes interact synergistically for the induction of severe, destructive Lyme arthritis. Infect Immun (1997) 0.82
2nd European Symposium on Lyme Borreliosis. A NATO advanced research workshop. United Kingdom, 19-20 May 1993. Abstracts. Ann Rheum Dis (1993) 0.81
Outer Surface Protein OspC Is an Antiphagocytic Factor That Protects Borrelia burgdorferi from Phagocytosis by Macrophages. Infect Immun (2015) 0.81
Macrophages exposed to Borrelia burgdorferi induce Lyme arthritis in hamsters. Infect Immun (1996) 0.80
Target shape dependence in a simple model of receptor-mediated endocytosis and phagocytosis. Proc Natl Acad Sci U S A (2016) 0.78
Fluorescent membrane markers elucidate the association of Borrelia burgdorferi with tick cell lines. Braz J Med Biol Res (2016) 0.75
Neutrophil extracellular traps involvement in corneal fungal infection. Mol Vis (2016) 0.75
Phagocytic receptors activate Syk and Src signaling during Borrelia burgdorferi phagocytosis. Infect Immun (2017) 0.75
Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med (1985) 20.49
Lyme disease. N Engl J Med (1989) 14.06
Formation of a novel phagosome by the Legionnaires' disease bacterium (Legionella pneumophila) in human monocytes. J Exp Med (1983) 7.65
Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci U S A (1990) 4.15
Phagocytosis of the Legionnaires' disease bacterium (Legionella pneumophila) occurs by a novel mechanism: engulfment within a pseudopod coil. Cell (1984) 4.00
Phagocytosis of Legionella pneumophila is mediated by human monocyte complement receptors. J Exp Med (1987) 3.78
Contractile proteins in leukocyte function. Semin Hematol (1983) 2.55
Laboratory aspects of Lyme borreliosis. Clin Microbiol Rev (1988) 2.18
Interactions of phagocytes with the Lyme disease spirochete: role of the Fc receptor. J Infect Dis (1984) 1.88
Lyme borreliosis: host responses to Borrelia burgdorferi. Microbiol Rev (1991) 1.87
Leishmania donovani: promastigote--macrophage surface interactions in vitro. Exp Parasitol (1979) 1.79
Experimental Borrelia burgdorferi infection in inbred mouse strains: antibody response and association of H-2 genes with resistance and susceptibility to development of arthritis. Eur J Immunol (1991) 1.71
Isolation of large numbers of fully viable human neutrophils: a preparative technique using percoll density gradient centrifugation. Exp Hematol (1982) 1.59
Characterization of Borrelia burgdorferi associated antigens by monoclonal antibodies. Immunobiology (1990) 1.37
Colloidal gold : a cytochemical marker for light and fluorescent microscopy and for transmission and scanning electron microscopy. Scan Electron Microsc (1981) 1.26
Human phagocyte interactions with the Lyme disease spirochete. Infect Immun (1984) 1.25
Demonstration of antigen-specific T cells and histopathological alterations in mice experimentally inoculated with Borrelia burgdorferi. Infect Immun (1989) 1.24
T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. Arthritis Rheum (1991) 1.23
Infectivity of Borrelia burgdorferi correlates with resistance to elimination by phagocytic cells. J Infect Dis (1991) 1.21
Ultrastructural and immunological aspects of the phagocytosis of Trypanosoma brucei by mouse peritoneal macrophages. Infect Immun (1978) 1.17
Cell propagation on films of polymeric fluorocarbon as a means to regulate pericellular pH and pO(2) in cultured monolayers. FEBS Lett (1971) 1.15
Rapid flow cytometric studies of Borrelia burgdorferi phagocytosis by human polymorphonuclear leukocytes. J Appl Bacteriol (1989) 1.00
[Serodiagnosis of Lyme borreliosis: antibody titer and specificity in the IFT and western blot]. Immun Infekt (1989) 0.92
Phagocytosis by fish cells. J Reticuloendothel Soc (1977) 0.91
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol (2001) 4.59
Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis (2001) 4.18
Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci U S A (1990) 4.15
Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol (1998) 3.98
Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin Infect Dis (1993) 3.92
Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol (1999) 3.68
Recombinant outer surface protein a from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. J Infect Dis (1991) 3.58
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum (1999) 3.42
Macrophages in rheumatoid arthritis. Arthritis Res (2000) 3.40
Specific Lyt 123 cells are involved in protection against Listeria monocytogenes and in delayed-type hypersensitivity to listerial antigens. J Exp Med (1979) 3.31
Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol (1983) 3.26
Lactase haplotype diversity in the Old World. Am J Hum Genet (2000) 3.19
Determination of arginase activity in macrophages: a micromethod. J Immunol Methods (1994) 3.16
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Molecular cloning and immunological characterization of a novel linear-plasmid-encoded gene, pG, of Borrelia burgdorferi expressed only in vivo. Infect Immun (1995) 3.00
Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med (1998) 2.89
The severe combined immunodeficiency (scid) mouse. A laboratory model for the analysis of Lyme arthritis and carditis. J Exp Med (1989) 2.68
Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum (2009) 2.57
Persistence of a behavioral food-anticipatory circadian rhythm following dorsomedial hypothalamic ablation in rats. Am J Physiol Regul Integr Comp Physiol (2006) 2.54
Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J (2001) 2.52
Mycobacterium-containing phagosomes are accessible to early endosomes and reflect a transitional state in normal phagosome biogenesis. EMBO J (1996) 2.52
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.51
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res (2001) 2.45
Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis. Arthritis Rheum (1981) 2.30
Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol (1999) 2.28
Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect (2011) 2.23
Lyme borreliosis in the severe combined immunodeficiency (scid) mouse manifests predominantly in the joints, heart, and liver. Am J Pathol (1990) 2.15
Q fever endocarditis in the United States. Ann Intern Med (1979) 2.12
Huntington's disease: genetic heterogeneity in black African patients. S Afr Med J (2008) 2.12
Identification of three major synovial lining cell populations by monoclonal antibodies directed to Ia antigens and antigens associated with monocytes/macrophages and fibroblasts. Scand J Immunol (1983) 2.10
Evaluation of genetic divergence among Borrelia burgdorferi isolates by use of OspA, fla, HSP60, and HSP70 gene probes. Infect Immun (1992) 2.10
The Borrelia burgdorferi flagellum-associated 41-kilodalton antigen (flagellin): molecular cloning, expression, and amplification of the gene. Infect Immun (1990) 2.10
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) (2007) 2.01
Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica (1997) 1.98
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum (1998) 1.90
Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun (1995) 1.89
Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol (1984) 1.87
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
Distinct patterns of protective antibodies are generated against Borrelia burgdorferi in mice experimentally inoculated with high and low doses of antigen. Immunol Lett (1993) 1.84
Mode of inoculation of the Lyme disease agent Borrelia burgdorferi influences infection and immune responses in inbred strains of mice. J Infect Dis (1993) 1.84
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen) receptor. Proc Natl Acad Sci U S A (1994) 1.76
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
[Amendment of the structural quality for inpatient rheumatology. A forward-looking concept]. Z Rheumatol (2011) 1.74
Functional characteristics of an endophyte community colonizing rice roots as revealed by metagenomic analysis. Mol Plant Microbe Interact (2012) 1.72
Experimental Borrelia burgdorferi infection in inbred mouse strains: antibody response and association of H-2 genes with resistance and susceptibility to development of arthritis. Eur J Immunol (1991) 1.71
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes. Exp Eye Res (1986) 1.70
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Molecular and immunological characterization of a novel polymorphic lipoprotein of Borrelia burgdorferi. Infect Immun (1993) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. Ann Rheum Dis (2002) 1.63
Grading of chronic synovitis--a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract (2002) 1.62
Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol (2001) 1.62
Subcutaneous crystal-storing histiocytosis associated with lymphoplasmacytic lymphoma (immunocytoma) Pathol Res Pract (1996) 1.57
Cloning and sequencing of the gene encoding the outer surface protein A (OspA) of a European Borrelia burgdorferi isolate. Nucleic Acids Res (1989) 1.53
Granzyme A-deficient mice retain potent cell-mediated cytotoxicity. EMBO J (1995) 1.52
A mouse model for Borrelia burgdorferi infection: approach to a vaccine against Lyme disease. Immunol Today (1991) 1.52
Molecular and biochemical characterization of a cytokinin oxidase from maize. Plant Physiol (2001) 1.52
GeneNest: automated generation and visualization of gene indices. Trends Genet (2000) 1.50
Therapeutic passive vaccination against chronic Lyme disease in mice. Proc Natl Acad Sci U S A (1997) 1.50
[Borrelia burgdorferi infection. I. Aspects of basic research, current approach for diagnosis and therapy]. Hautarzt (1990) 1.49
Interleukin 2 induction in Lyt 1+ 23- T cells from Listeria monocytogenes-immune mice. Infect Immun (1982) 1.49
Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today (2000) 1.48
Association of citrullinated proteins with synovial exosomes. Arthritis Rheum (2006) 1.48
Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci U S A (1999) 1.46
Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis (2012) 1.46
Breast reconstruction with latissimus dorsi flap: improved aesthetic results after transection of its humeral insertion. Plast Reconstr Surg (1999) 1.46
The immune response of the mouse to lymphocytic choriomeningitis virus. V. High numbers of cytolytic T lymphocytes are generated in the spleen during acute infection. Eur J Immunol (1987) 1.46
Photic modulation of a highly sensitive, near-infrared light-scattering signal recorded from intact retinal photoreceptors. Proc Natl Acad Sci U S A (1988) 1.46
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis (2011) 1.46
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum (1991) 1.45